{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Halappanavar S"],"funding":["Health Canada’s Genomics Research and Development Initiative","Health Canada and Environment and Climate Change Canada","Intramural CDC HHS","NanoCommons"],"pagination":["289-310"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8630540"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(3)"],"pubmed_abstract":["Significant advances have been made in the development of Adverse Outcome Pathways (AOPs) over the last decade, mainly focused on the toxicity mechanisms of chemicals. These AOPs, although relevant to manufactured nanomaterials (MNs), do not currently capture the reported roles of size-associated properties of MNs on toxicity. Moreover, some AOs of relevance to airborne exposures to MNs such as lung inflammation and fibrosis shown in animal studies may not be targeted in routine regulatory decision making. The primary objective of the present study was to establish an approach to advance the development of AOPs of relevance to MNs using existing, publicly available, nanotoxicology literature. A systematic methodology was created for curating, organizing and applying the available literatur"],"journal":["Nanotoxicology"],"pubmed_title":["A methodology for developing key events to advance nanomaterial-relevant adverse outcome pathways to inform risk assessment."],"pmcid":["PMC8630540"],"funding_grant_id":["CC999999","731032"],"pubmed_authors":["Kuempel ED","Vandebriel RJ","Halappanavar S","Ede JD","Mahapatra I","Shatkin JA","Krug HF","Lynch I"],"additional_accession":[]},"is_claimable":false,"name":"A methodology for developing key events to advance nanomaterial-relevant adverse outcome pathways to inform risk assessment.","description":"Significant advances have been made in the development of Adverse Outcome Pathways (AOPs) over the last decade, mainly focused on the toxicity mechanisms of chemicals. These AOPs, although relevant to manufactured nanomaterials (MNs), do not currently capture the reported roles of size-associated properties of MNs on toxicity. Moreover, some AOs of relevance to airborne exposures to MNs such as lung inflammation and fibrosis shown in animal studies may not be targeted in routine regulatory decision making. The primary objective of the present study was to establish an approach to advance the development of AOPs of relevance to MNs using existing, publicly available, nanotoxicology literature. A systematic methodology was created for curating, organizing and applying the available literatur","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-04-22T09:15:48.35Z","creation":"2025-04-05T22:59:35.381Z"},"accession":"S-EPMC8630540","cross_references":{"pubmed":["33317378"],"doi":["10.1080/17435390.2020.1851419"]}}